Cancer bronchique à petites cellules : avancées et défis (notice n° 271028)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02694cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112080447.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ouali, Kaissa |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Cancer bronchique à petites cellules : avancées et défis |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 81 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméLe cancer bronchique à petites cellules (CBPC), bien que peu fréquent, reste l’un des cancers les plus agressifs et les plus difficiles à traiter, du fait du taux élevé de rechute et du faible arsenal thérapeutique. Les avancées en termes de traitements systémiques, en particulier l’avènement de l’immunothérapie, sont pourtant en train de bousculer le traitement standard de première ligne qui ne reposait alors que sur la chimiothérapie. La recherche de marqueurs prédictifs de réponse et pronostiques fait apparaître le CBPC comme une entité dissociée des autres tumeurs, avec un rôle clé de l’infiltrat immunitaire, au profit des marqueurs usuels tels que le statut PD-L1 (programmed death-ligand 1) ou le TMB (tumour mutational burden). Les dernières avancées en termes d’analyse génomique ont, par ailleurs, permis de réaliser une classification moléculaire des CBPC, qui met en avant de nouveaux horizons thérapeutiques. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Small cell lung cancer (SCLC), although uncommon, remains one of the most aggressive and difficult cancers to treat due to the high rate of relapse and few therapeutic options. Advances in systemic treatments, and in particular the advent of immunotherapy, are completely changing standard first-line treatment, which previously relied only on chemotherapy. The search for predictive markers of response and prognosis highlights SCLC as an entity distinct from other tumours, in which tumor-infiltrating lymphocytes play a key role, compared to the usual markers, such as PD-L1 (programmed death-ligand 1) status or tumour mutational burden. The latest advances in terms of genomic analysis have also made it possible to carry out a molecular classification of SCLC, which is leading to new therapeutic horizons. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biomarqueurs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer bronchique à petites cellules |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti-PD-L1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti-PD-1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti PD-L1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | small cell lung cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biomarkers |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti PD-1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunotherapy |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Baldini, Capucine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 6 | 6 | 2020-11-01 | p. 258-264 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2020-6-page-258?lang=fr">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2020-6-page-258?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux